Avalyn Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Lyn Baranowski
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 24.80% |
| CEO tenure | 3.7yrs |
| CEO ownership | n/a |
| Management average tenure | 2.6yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$510k | -US$85m |
Compensation vs Market: Lyn's total compensation ($USD2.06M) is below average for companies of similar size in the US market ($USD3.64M).
Compensation vs Earnings: Insufficient data to compare Lyn's compensation with company performance.
CEO
Lyn Baranowski (50 yo)
Ms. Lyn Baranowski serves as the Chief Executive Officer for Avalyn Pharma, Inc. since joined in October 2022 and also serves as its President and Director since October 2022. She was Director at Rani Ther...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.7yrs | US$2.06m | no data | |
| CFO & Chief Business Officer | 2.1yrs | US$905.90k | 0% $ 0 | |
| Chief Operating Officer | 2.8yrs | US$967.47k | 0% $ 0 | |
| Chief Medical Officer | 2.8yrs | US$740.90k | 0% $ 0 | |
| Senior Director of IR & Corporate Communications | no data | no data | no data | |
| General Counsel & Head of Business Development | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | 2.6yrs | no data | no data | |
| Senior Vice President of Business Operations | 2.7yrs | no data | no data | |
| Senior Vice President of Product Development | no data | no data | no data | |
| Senior Vice President of Corporate Planning & Portfolio Strategy | no data | no data | no data | |
| Senior Vice President of Clinical Development Operations | less than a year | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data |
Experienced Management: AVLN's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.7yrs | US$2.06m | no data | |
| Independent Director | 1.2yrs | no data | no data | |
| Independent Chairman | 1.7yrs | US$40.00k | 0% $ 0 | |
| Independent Director | 2.8yrs | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 1.9yrs | US$25.00k | 0% $ 0 | |
| Board Observer | no data | no data | no data |
Experienced Board: AVLN's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 15:37 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avalyn Pharma Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gavin Clark-Gartner | Evercore ISI |
| Seamus Fernandez | Guggenheim Securities, LLC |
| Roger Song | Jefferies LLC |